Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07594626 · ClinicalTrials.gov registry record · Phase 1
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
A Phase 1 study, sponsored by Northwestern University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07594626 is a Phase 1 study that has not yet begun recruiting, run by Northwestern University. The registered enrollment target is 72 participants.
The verdict
NCT07594626, a Phase 1 study, has not yet begun recruiting, sponsored by Northwestern University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This phase Ib/II trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it first started (primary site) to other places in the body (metastatic). The MTAP gene helps cells recycle important parts needed to make deoxyribonucleic acid (DNA), which is needed for cell growth and function. MTAP deletion means that the MTAP gene is missing. BMS-986504, a PRMT5 inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Giving BMS-986504 in combination with pemetrexed may be safe, tolerable, and/or effective in treating patients with metastatic solid tumors with MTAP deletion.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- DRUG Pemetrexed
- DRUG PRMT5 Inhibitor BMS-986504
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2027-12-09 |
| Est. Completion | 2030-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07594626
The ClinicalTrials.gov registry entry for NCT07594626 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT07594626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07594626 about?
NCT07594626 is a clinical study titled "BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion". This phase Ib/II trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it first started (primary site) to other places in the body (metastatic). ...
What is the current status of trial NCT07594626?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2027-12-09. Estimated completion is 2030-12-09.
What interventions are being tested in trial NCT07594626?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Pemetrexed (DRUG), PRMT5 Inhibitor BMS-986504 (DRUG).
Who is sponsoring clinical trial NCT07594626?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.